Harrow, Inc. (HROW)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $1.24B
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
Latest financial period: June 30, 2026
Filed with the SEC: August 10, 2026
Estimated earnings date: November 9, 2026
Profit #1360 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 6.3% | 9.7% | 14.5% | 12.0% |
Growth #192 of 1484 companies
Payout #1117 of 1484 companies
Safety #1451 of 1484 companies
Price #1352 of 1484 companies
